IP Library Granted Patent US 8,247,374
Granted Patent B2
US 8,247,374 · App. 12/267,849 · Granted Aug 21, 2012

Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof

Assignee: New York Medical College
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,247,374
App. No.
12/267,849
Granted
Aug 21, 2012
Kind
B2
Abstract

Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.

Claims (27)

1. A method for restoring functional and structural integrity to damaged myocardium in a subject in need thereof, the method comprising administering to the subject an effective amount of at least one variant of hepatocyte growth factor selected from the group consisting of NK1, 1K1, 1K2, HP11, HP12, and HP21 to form a chemotactic gradient in the subject's heart sufficient to cause adult cardiac stem cells resident in the heart to replicate and migrate to the area of the damaged myocardium, wherein the functional and structural integrity of the damaged myocardium is restored following the migration of adult cardiac stem cells to the area of damaged myocardium.

2. The method of claim 1 , wherein said stem cells are c-kit Pos .

3. The method of claim 1 , wherein the administering is by injection.

4. The method of claim 3 , wherein the injection is intramyocardial.

5. The method of claim 3 , wherein the injection is trans-epicardial.

6. The method of claim 1 , wherein the administering is via a catheter.

7. The method of claim 1 , wherein the adult cardiac stem cells differentiate into myocytes, smooth muscle cells, and endothelial cells.

8. The method of claim 7 wherein at least some of the differentiated adult cardiac stem cells assemble into myocardial tissue and myocardial vessels.

9. The method of claim 1 , wherein said method also regenerates cardiac vessels.

10. The method of claim 1 , wherein the at least one variant of hepatocyte growth factor is administered at varying concentrations of about 0.1 to about 400 ng/ml at different places of administration.

11. The method of claim 10 , wherein the varying concentrations of the at least one variant of hepatocyte growth factor increase progressively in a direction towards the damaged myocardium.

12. The method of claim 10 wherein said at least one variant of hepatocyte growth factor is administered at varying concentrations of about 50 to about 200 ng/ml at different places of administration.

13. The method of claim 1 , further comprising administering a second cytokine, wherein the second cytokine induces proliferation of adult cardiac stem cells.

14. The method of claim 13 , wherein the second cytokine is insulin-like growth factor-1.

15. The method of claim 14 , wherein the insulin-like growth factor-1 is administered at a concentration from about 0.1 ng/ml to about 500 ng/ml.

16. The method of claim 15 , wherein the insulin-like growth factor-1 is administered at a concentration from about 150 ng/ml to about 250 ng/ml.

17. The method of claim 16 , wherein the insulin-like growth factor-1 is administered at a concentration of about 200 ng/ml.

18. The method of claim 1 , wherein said variant of hepatocyte growth factor is HP11.

19. The method of claim 1 , wherein said variant of hepatocyte growth factor is HP21.

20. A method for restoring functional and structural integrity to damaged myocardium in a subject in need thereof, the method comprising administering to the subject an effective amount of at least one variant of hepatocyte growth factor selected from the group consisting of NK1, 1K1, 1K2, HP11, HP12, and HP21 to form a chemotactic gradient in the subject's heart sufficient to cause adult cardiac stem cells resident in the heart to replicate and migrate to the area of the damaged myocardium, wherein said gradient is formed by multiple injections of said at least one variant of hepatocyte growth factor from storage areas of said resident adult cardiac stem cells to a border zone of the damaged myocardium, and wherein the functional and structural integrity of the damaged myocardium is restored following the migration of adult cardiac stem cells to the area of damaged myocardium.

21. The method of claim 20 , wherein the multiple injections comprise variable concentrations of said variant of hepatocyte growth factor.

22. The method of claim 20 , wherein the storage areas of said resident adult cardiac stem cells are one or more of the subject's myocardial apex, left atrium, and right atrium.

23. The method of claim 20 , wherein at least two of the injections are done at opposite sides of the border zone.

24. The method of claim 20 , further comprising administering a second cytokine, wherein the second cytokine induces proliferation of adult cardiac stem cells.

25. The method of claim 24 , wherein the second cytokine is insulin-like growth factor-1.

26. The method of claim 20 , wherein said variant of hepatocyte growth factor is HP11.

27. The method of claim 20 , wherein said variant of hepatocyte growth factor is HP21.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2009
From: ANVERSA, PIERO, DR.
To: NEW YORK MEDICAL COLLEGE
Reel/Frame 022188/0567 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2009
From: ANVERSA, PIERO, DR.
To: NEW YORK MEDICAL COLLEGE
Reel/Frame 022088/0911 →
LICENSE Recorded Jan 12, 2009
From: NEW YORK MEDICAL COLLEGE
To: AUTOLOGOUS REGENERATION, LLC
Reel/Frame 022089/0073 →
Continuity (2)
Provisional Application 60986788 · Nov 9, 2007
Related Publication 20090157046A1 · Jun 18, 2009